Jeffrey P. MacKeigan, PhD, completed his undergraduate training in molecular, cellular and developmental biology at the University of Colorado in Boulder, Colorado. In 2002, he received his PhD in microbiology and immunology from the University of North Carolina. Dr. MacKeigan then served as a postdoctoral fellow in the Department of Cell Biology at Harvard Medical School. In 2004, he joined Novartis Institutes for Biomedical Research in Cambridge, Massachusetts, as a project leader in the Molecular and Developmental Pathways expertise platform. Dr. MacKeigan joined Van Andel Research Institute in June 2006 and Michigan State University in 2017 as professor of cancer biology and complex diseases. His research focuses on studying drug targets for neurological disorders and on designing neuroprotective strategies for the treatment of Parkinson's disease.